2021 American Transplant Congress
Application of Linear Discriminant Analysis (lda) to Differentiate Acute Rejection (ar) and Acute Dysfunction Non-Rejection (adnr) in Liver Transplant Recipients
*Purpose: Blood-based biomarkers distinguishing acute-rejection (AR) from other causes of graft dysfunction (acute dysfunction non-rejection (ADNR)) would have significant clinical applicability in liver transplant (LT)…2021 American Transplant Congress
Management of Drug Interactions During Protocolized Implementation of Posaconazole Immediately Post Heart Transplant
Massachusetts General Hospital, Boston, MA
*Purpose: Posaconazole (POSA) is a strong CYP3A4 inhibitor known to increase tacrolimus exposure by up to 4-fold. Initiation requires empiric tacrolimus dose adjustment and close…2021 American Transplant Congress
A Mechanistic Evaluation to Guide the Optimal Immunosuppression Adjustment Strategy in Transplant Patients with COVID-19
*Purpose: The optimal management of immunosuppression in transplant patients infected with COVID-19 is unknown. Reduction in calcineurin inhibitors or antimetabolite doses is often performed in…2021 American Transplant Congress
Primary Outcome of OPTIMAL: A Prospective Multicenter Trial of Immunosuppression Withdrawal (ISW) in Stable Adult Liver Transplant (LT) Recipients
1ITN, San Francisco, CA, 2Rho, Inc., Durham, NC, 3MGH, Boston, MA
*Purpose: To identify clinical & mechanistic correlates of successful ISW and operational tolerance (OT) in a selected cohort of adult LT recipients.*Methods: The Immune Tolerance…2021 American Transplant Congress
CD80/PD-L1 Uniquely Regulates CD4 Effector T Cell Migration
1U Maryland, baltimore, MD, 2U Minnesota, Minneapolis, MN, 3Harvard U, boston, MA
*Purpose: CD80 is a costimulatory molecule expressed on antigen presenting cells (APCs) that binds CD28 and CTLA4, stimulating or inhibiting immunity, respectively. CD80 also binds…2021 American Transplant Congress
Changes in Cytomegalovirus Specific T Cell Immunity With Immunomodulation in Serodiscordant High Risk Transplant Recipients
Virginia Commonwealth University Health, Richmond, VA
*Purpose: Cytomegalovirus (CMV) infections cause significant morbidity and mortality among all solid organ transplant recipients. CMV discordant (D+/R-) recipients are at higher risk of developing…2021 American Transplant Congress
A Comparison of Belatacept Conversion Regimens from Calcineurin Inhibitor-Based Immunosuppression
Cedars-Sinai Medical Center, Los Angeles, CA
*Purpose: Outcomes with varying belatacept conversion protocols from calcineurin inhibitor (CNI)-based immunosuppression have been published but no standard protocol has been established. Beginning in 2012,…2021 American Transplant Congress
A Case-Match Cohort Comparison of the Safety and Efficacy of Basiliximab for Immunosuppression Holiday in Lung Transplant Patients
1Pharmacy, Massachusetts General Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA
*Purpose: Post-transplant complications related to calcineurin inhibitors (CNI) maintenance immunosuppression (MI) may require interim alternative therapies. The goal of this study is to evaluate the…2021 American Transplant Congress
Clinical and Molecular Profiling Can Help in Predicting the Response to Alemtuzumab Treatment in Kidney Transplant Recipients with Severe or Glucocorticoid-Resistant Acute Rejection
*Purpose: Alemtuzumab is an effective drug for the treatment of severe or glucocorticoid-resistant acute kidney allograft rejection (AR), but can also cause severe adverse events.…2021 American Transplant Congress
Dd-cfdna Can Guide Safe Reintroduction of Immunosuppression in Kidney Transplant Recipients with Covid-19
1CareDx, Brisbane, CA, 2Transplant Institute, NYU Langone Health, New York, NY
*Purpose: COVID-19 infection is associated with 25% mortality in kidney transplant recipients (KTRs). Reduction of anti-metabolite immunosuppressants during the acute COVID-19 illness is a common…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 138
- Next Page »